Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Cervical cancer screening

04.11.2003


No proven benefit of detection of human papillomavirus alone compared with the conventional Pap smear

Under the aegis of the French Society of Clinical Cytology, physicians at the Institut Curie have evaluated the relevance of the papillomavirus detection test, Hybrid Capture‚ II, in screening for cervical cancer, the second most common cancer in women worldwide. They have shown that this test cannot replace cytological analysis of the cervical smear.
For the first time a learned society, the French Society of Clinical Cytology, has organized a multicenter, national study in general practice. Cervical cancer screening is one of 70 priority measures in France’s Cancer Plan, and an important goal is to establish a test that combines reliability, feasibility and affordability. This work was published in the October 2003 issue of the American Journal of Clinical Pathology.


Cervical cancer is the second most common cancer in women, with 465 000 new cases and 200 000 deaths worldwide every year. In France, 3 387 new cases and 1 000 deaths were recorded in 2000. Cervical cancer affects women in all age ranges, from 25 years upwards.

Cervical cancer screening: a national priority

Early detection of cervical cancer through intensified screening is one of the 70 measures of the Cancer Plan launched in France by the President of the Republic. Screening is based on the cervical smear test. In this simple and painless test, cells are collected from the surface of the cervix and are examined under the microscope for any anomaly suggestive of lesions that are precancerous or cancerous. It should be performed every three years.

The Cancer Plan is intended to broaden availability of the smear test (family planning, occupational medicine...) to women who do not have a gynecologist, so as to intensify information actions and facilitate testing for papillomavirus infection.
In France, generalization of the smear test has already led to a reduction in the incidence of cervical cancer: the number of cases decreased from 5 992 in 1975 to 3 387 in 2000, i.e. a 46 % decrease in 25 years.

This incidence though is still high, possibly due to the fact that the female population is not fully covered and also because some women develop cervical cancer despite regular smear tests, which clearly have shortcomings (false-negatives, absence of abnormal cells in the area of the smear…). Screening should be improved by the implementation of more sensitive tests.

Comparison of detection of HPV and cytologic analysis

Close to 90% of cervical cancers develop from pre-invasive lesions due to a human papillomavirus (HPV). The efficiency of screening could be improved by the inclusion of testing for HPV.

Under the aegis of the French Society of Clinical Cytology, physicians of the Institut Curie, coordinated by Dr Béatrix Cochand-Priollet (1) have evaluated the efficiency and relevance of the Hybrid Capture‚ II papillomavirus DNA test (HC-II) (2). This test performed on the cervical smear detects papillomavirus DNA and distinguishes high-risk from low-risk HPVs.

By comparing cytologic analyses and the HC-II test in 1 785 patients, the Institut Curie physicians have shown that the HC-II test performed alone is less sensitive than cytologic analysis of a cervical smear.

In conclusion, comparative analysis of the sensitivity and specificity of the HC-II technique and of the conventional Pap smear reveals no advantage of HPV detection alone in the framework of cervical cancer screening.

It is therefore unlikely that the HC-II test will replace cytologic analysis, but it could in certain cases be complementary. Further studies are needed to define the role of the HC-II test in cervical cancer screening and follow-up.


Note

(1) Dr Béatrix Cochand-Priollet works in the Pathological Anatomy and Cytology Department of the Hôpital Lariboisière.
(2) This test is manufactured by Digene“ (Gaithersburg, USA).

Catherine Goupillon | Institut Curie

More articles from Health and Medicine:

nachricht The end of pneumonia? New vaccine offers hope
23.10.2017 | University at Buffalo

nachricht Scientists track ovarian cancers to site of origin: Fallopian tubes
23.10.2017 | Johns Hopkins Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Salmonella as a tumour medication

HZI researchers developed a bacterial strain that can be used in cancer therapy

Salmonellae are dangerous pathogens that enter the body via contaminated food and can cause severe infections. But these bacteria are also known to target...

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

3rd Symposium on Driving Simulation

23.10.2017 | Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

 
Latest News

Shrews shrink in winter and regrow in spring

24.10.2017 | Life Sciences

Microfluidics probe 'cholesterol' of the oil industry

23.10.2017 | Life Sciences

Gamma rays will reach beyond the limits of light

23.10.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>